Androgen deprivation therapy (ADT) for prostate cancer may be associated with a reduced risk of inflammatory bowel disease (IBD), according a recent report in the American Journal of Epidemiology (2016;184:15-22).
In a study of 31842 men newly diagnosed with prostate cancer, Laurent Azoulay, MD, of Jewish General Hospital in Montreal, and colleagues found men exposed to ADT had a significant 48% decreased risk of ulcerative colitis and a non-significant 62% decreased risk of Crohn’s disease.
“These findings indicate that the use of ADT may be associated with intestinal autoimmunity,” the researchers concluded.
Continue Reading
